Arthritis Care & Research最新文献

{"title":"Clinical Significance of Therapeutic Drug Level Monitoring for Mycophenolate in Patients With Extrarenal Systemic Lupus Erythematosus-A Systematic Review and Meta-Analysis.","authors":"Zahraa Qamhieh, Dalia Sriwi, Callie Saric, Tripti Singh, Christie M Bartels, Shivani Garg","doi":"10.1002/acr.80035","DOIUrl":"10.1002/acr.80035","url":null,"abstract":"<p><strong>Objective: </strong>Clinical response to mycophenolic acid (MPA) is highly heterogeneous; thus, therapeutic drug level monitoring (TDM) may help improve treatment efficacy. This systematic review and meta-analysis examined therapeutic ranges for MPA levels associated with better outcomes and safety in patients with systemic lupus erythematosus (SLE), particularly those with extrarenal manifestations.</p><p><strong>Methods: </strong>We performed a comprehensive search of studies evaluating associations between MPA levels and clinical SLE response. Using forest plots, we calculated pooled odds of clinical response by MPA levels and measured the weighted mean differences across outcomes. Analysis was performed in all patients with SLE and separately in patients with extrarenal manifestations.</p><p><strong>Results: </strong>Among 459 reviewed abstracts, 24 met inclusion. Summarized evidence supported that clinical response was observed at MPA area under the curve at 0 to 12 hours (AUC_0-12) ≥30 to 35 mg hr/L or trough concentration (C_trough) ≥1.5 mg/L. At these thresholds, therapeutic MPA levels were associated with 12-fold higher odds (95% confidence interval [CI] 5.44-27.35; P < 0.0001; I² = 41%) of overall clinical SLE response and 15-fold higher odds (95% CI 4.74-46.89; P < 0.0001; I² = 61%) of response in patients with extrarenal manifestations. Additionally, MPA levels were 32 units higher (95% CIs 17.35-45.67) in overall responders with SLE and 39 units (95% CI 15.05-62.53) higher in patients with extrarenal manifestations. Although pooled analysis did not show a significant increase in adverse events, individual studies suggested safety concerns at MPA AUC_0-12 >60 mg hr/L or C_trough ≥2.5 to 3 mg/L CONCLUSION: This study highlights the clinical utility of TDM to guide MPA dosing to balance efficacy versus safety in all patients with SLE, including those with extrarenal manifestations.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147375872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trajectories of Physical Function in Canadian Children with Juvenile Idiopathic Arthritis.","authors":"Clare Cunningham, Meghan McPherson, Lillian Lim, Roberta A Berard, Matthew Berkowitz, Jean-Philippe Proulx-Gauthier, Brian M Feldman, Nicole Johnson, Dax G Rumsey, Heinrike Schmeling, Lori B Tucker, Thomas Loughin, Kristin M Houghton, Jaime Guzman","doi":"10.1002/acr.80039","DOIUrl":"10.1002/acr.80039","url":null,"abstract":"<p><strong>Objectives: </strong>We describe trajectories of physical function in children newly diagnosed with juvenile idiopathic arthritis (JIA) and identify trajectories with persisting functional impairments and associated baseline characteristics.</p><p><strong>Methods: </strong>We included patients enrolled in the Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) Registry between 2017 and 2024, whose parents provided Kids Disability Screen scores in at least two visits (KDS, from 0=no disability to 10=severe disability). Analyses included descriptive statistics, locally weighted scatterplot smoothing (LOWESS), Kaplan-Meier plots of time to KDS=0, latent class trajectory analysis (LCTA), and classification trees to predict trajectories with persisting impairments.</p><p><strong>Results: </strong>We included 940 patients providing 7,351 KDS scores starting a median 6 days after diagnosis up to 7 years. Baseline KDS scores were highest for RF-positive polyarthritis (mean 4.9, SD 3.1) and lowest for psoriatic arthritis (mean 2.4, SD 2.5), and mean scores improved within the first year in all JIA categories. Median time to KDS=0 was 36 weeks (from 13w for systemic arthritis to 73w for undifferentiated arthritis). LCTA identified 5 trajectories: one with little measurable impairment (38% of patients), two with impairments resolving in 1-2 years (24%), and two with persisting mild impairments (38%). A baseline KDS≥1.5 had a sensitivity of 0.79 and specificity of 0.48 to detect persisting mild impairment trajectories. There were no trajectories with persisting moderate or severe impairments.</p><p><strong>Conclusion: </strong>Most children with JIA in this cohort had mild to moderate functional impairments at diagnosis that resolved in 1-2 years, but 1 in 3 followed trajectories with mild persisting impairments.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147375877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Performance of LFA-REAL, SLEDAI, and BILAG for Detecting Clinically Meaningful Changes in Lupus Activity.","authors":"Alberto Nordmann-Gomes, Leila Khalili, Cynthia Aranow, Meggan Mackay, Mimi Kim, Diane Kamen, Cristina Arriens, Maya Souvignier, Wei Tang, Stephen Suh, Robert Clancy, Cady Chen, Maria Dall'Era, Joan T Merrill, Anca D Askanase","doi":"10.1002/acr.80034","DOIUrl":"10.1002/acr.80034","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to compare the performance of the Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL), British Isles Lupus Assessment Group Index (BILAG), and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) in detecting the clinician's perception of improvement and worsening disease and identifying patients requiring treatment escalation.</p><p><strong>Methods: </strong>This was a prospective, observational study conducted at four centers. Adults with systemic lupus erythematosus were evaluated at a baseline and follow-up visit. Disease activity was assessed using SLEDAI, BILAG, and LFA-REAL at both visits by the same physician. At the follow-up visit, the Clinician Global Impression of Change (CGIC) was recorded to classify patients as improved, worsened, or unchanged. Receiver operating characteristic curve analysis was used to evaluate each instrument in detecting clinician-rated change gauged by CGIC with optimal cut-off points determined using the Youden Index.</p><p><strong>Results: </strong>Of the 163 patients enrolled, 145 (89%) completed a follow-up visit. Based on CGIC, 23% improved, 16% worsened, and 61% remained stable. For detecting CGIC-defined improvement, LFA-REAL had an area under the curve (AUC) of 0.85 (95% confidence interval [CI] 0.77-0.92), compared to 0.75 (95% CI 0.66-0.85) for BILAG and 0.74 (95% CI 0.64-0.84) for SLEDAI. For CGIC-defined worsening, AUCs were 0.86 (95% CI 0.77-0.96), 0.79 (95% CI 0.67-0.90), and 0.76 (95% CI 0.66-0.87). Of those with CGIC-defined worsening, eight (35%) required treatment escalation. LFA-REAL identified a difference of ≥10 mm in all eight of these patients, compared to four by BILAG and two by SLEDAI.</p><p><strong>Conclusion: </strong>LFA-REAL showed comparable performance relative to SLEDAI and BILAG in detecting clinician-rated change. There was a statistically significant advantage over SLEDAI for detection of improvement. These findings support its utility as a metric for disease activity in clinical practice and research.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147375841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Developing and Evaluating a Laboratory-Based Frailty Index for the Prediction of Long-Term Health Outcomes in Systemic Lupus Erythematosus.","authors":"Grace Burns, Samuel D Searle, Alexandra Legge","doi":"10.1002/acr.80036","DOIUrl":"10.1002/acr.80036","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to construct and evaluate the first laboratory-based frailty index (FI-Lab) for predicting adverse outcomes in systemic lupus erythematosus (SLE) and to compare its predictive ability to that of an existing clinical FI.</p><p><strong>Methods: </strong>We used data from a single-center prospective cohort of adult patients with SLE whose baseline visit occurred between 2010 and 2019. A 30-item FI-Lab was constructed by adapting an existing list of FI-Lab variables. Cox proportional hazards regression examined the association between baseline FI-Lab scores and all-cause mortality, whereas negative binomial regression evaluated the association with organ damage accrual. We compared the performance of multivariable models containing the FI-Lab and/or Systemic Lupus International Collaborating Clinics FI as predictor variables using Akaike information criterion, Harrell's C-statistic, and pseudo-R² values.</p><p><strong>Results: </strong>Among 283 patients (89% women, mean age 47.7 years), 97 were classified as frail at baseline (FI-Lab >0.21). Frail individuals had increased mortality risk (hazard ratio 3.71, 95% confidence interval [CI] 1.82-7.54) and a higher rate of organ damage accrual during follow-up (incidence rate ratio 2.26; 95% CI 1.59-3.22) compared to nonfrail patients. The FI-Lab remained significantly associated with mortality risk after multivariable adjustment. Although both indices were significant baseline predictors of organ damage accrual during follow-up, the multivariable model containing both FIs outperformed models containing either index alone.</p><p><strong>Conclusion: </strong>An FI constructed exclusively from routinely collected laboratory variables can measure frailty and predict adverse outcomes in SLE. It may serve as a convenient screening tool to detect subclinical frailty and promote early risk mitigation in this population.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147375895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Retinopathy Associated with Long-Term Use of Hydroxychloroquine in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis.","authors":"Narsis Daftarian, Chloe Yue, Steve D Levasseur, Hui Xie, J Antonio Avina-Zubieta","doi":"10.1002/acr.80033","DOIUrl":"10.1002/acr.80033","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to estimate the prevalence and cumulative incidence of hydroxychloroquine retinopathy (HCQ-R) and its risk factors among patients receiving long-term HCQ with rheumatic diseases through a systematic review and meta-analysis of observational studies that used spectral-domain optical coherence tomography (SD-OCT) for screening.</p><p><strong>Methods: </strong>A systematic search of PubMed, Scopus, Ovid EMBASE, and World Health Organization databases (inception-December 31, 2025) identified observational studies meeting the following criteria: 1) adults with rheumatic diseases on HCQ for at least one year, 2) SD-OCT used for HCQ-R screening, 3) reported HCQ-R prevalence or cumulative incidence or calculable data, 4) reported HCQ-R risk factors as hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs), and 5) English full text. Study quality was assessed using the Newcastle-Ottawa Scale. Random-effects meta-analysis estimated pooled prevalence, cumulative incidence, and risk-factor associations.</p><p><strong>Results: </strong>We screened 827 studies from which an overall 19 met inclusion criteria (18 cohort and 1 case-control). Pooled HCQ-R prevalence from 2008 to 2023 was 5.1% (95% CI 3.9-6.5). Pooled cumulative incidence was 0.1% (95% CI 0.0-0.5) at 5 years, 2.6% (95% CI 1.6-4.1) at 10 years, and 5.6% (95% CI 3.2-9.6) at 15 years. Risk factors measured as HR (95% CI) included daily dose >5 mg/kg actual body weight (4.32 [2.80-6.65]), chronic kidney disease (CKD) (1.94 [1.27-2.96]), female sex (3.78 [1.90-7.48]), and Asian vs White ethnicity (1.67 [1.07-2.62]).</p><p><strong>Conclusion: </strong>HCQ-R risk increases with duration and is dose-dependent, reaching 5.6% by 15 years. Findings support dose optimization with intensified screening for higher-risk patients, including those with CKD or those who are female and/or Asian.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147363612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standardized Interoperable Data Collection for Myositis Research: Developing Expert Consensus on Common Data Elements for Myositis Outcome Measures.","authors":"Didem Saygin, Matthew Diller, Varsha Surampudi, Mark Bodkin, Payam Noroozi Farhadi, Christopher A Mecoli, Audrey Kessel, Rohit Aggarwal, Helene Alexanderson, Anthony Amato, Christie M Bartels, Olivier Benveniste, Michelle Best, Hector Chinoy, Ingrid de Groot, Brian Feldman, Adam M Huber, Hanna Kim, Susan Kim, Linda Kobert, Valerie Leclair, Manuel Lubinus, Pedro M Machado, Andrew Mammen, Liza J McCann, Tahseen Mozaffar, Chester Oddis, Julie J Paik, Angelo Ravelli, Nicolino Ruperto, Jens Schmidt, Ellen Werner, Victoria Werth, Adam Schiffenbauer, Richard H Scheuermann, Lisa G Rider","doi":"10.1002/acr.80032","DOIUrl":"10.1002/acr.80032","url":null,"abstract":"<p><strong>Objective: </strong>Recent progress has been made in developing validated myositis outcome measures. However, critical deficiencies remain for data standardization across myositis registries. Although the National Institutes of Health (NIH) Common Data Elements (CDE) Repository has been developed to facilitate standardized data collection and sharing, few myositis-specific CDEs currently exist. We developed CDEs for myositis outcome measures using novel data science strategies.</p><p><strong>Methods: </strong>Data dictionaries of myositis registries were examined to understand how outcome measures are currently captured. We used the Linked data Modeling Language, an open-source data modeling framework, to develop computable CDEs. After drafting CDEs for myositis core set measures (CSMs), an international conference was held with an expert myositis panel to reach consensus on the coding of CDEs and prioritize additional measures for CDE creation, using Delphi and modified nominal group techniques. This workflow was repeated for the prioritized measures in the second phase.</p><p><strong>Results: </strong>A workflow was established for CDE creation. CDEs for 10 myositis CSMs were drafted. After receiving comments to improve their coding, universal agreement among participants was reached for CSM CDEs. The prioritized measures for future CDEs included myositis response and classification criteria, damage measures, physical function measures, and Patient-Reported Outcomes Measurement Information System instruments. CDEs for 18 additional measures were discussed at a second consensus conference. Similarly, high agreement rates were achieved, except for flare criteria. Altogether, 852 new CDEs were created for 27 myositis forms and achieved consensus, readying their deposit in the NIH CDE Repository.</p><p><strong>Conclusion: </strong>Leveraging multispecialty expertise in myositis and its patient communities and data science expertise of the National Library of Medicine, the first myositis-specific CDEs have been developed to accelerate the ability to conduct interoperable myositis clinical studies and therapeutic trials. The workflow established here should also benefit creation of CDEs and data sharing for other autoimmune diseases.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13050307/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147363835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Formal and informal social care in people with Rheumatic and Musculoskeletal diseases: a cross-sectional multicentre survey.","authors":"Mehreen Somro, Karen Durrant, William G Dixon, John McBeth, Alex MacGregor, Max Yates, Jenny H Humphreys","doi":"10.1002/acr.80031","DOIUrl":"https://doi.org/10.1002/acr.80031","url":null,"abstract":"<p><strong>Introduction: </strong>Rheumatic and musculoskeletal diseases(RMDs) are leading causes of physical disability, necessitating support with activities of daily living(ADLs). This study describes social care received by patients with RMDs in two disperate regions of England: Salford(urban) and Norfolk(rural).</p><p><strong>Methods: </strong>A cross-sectional survey identified how many patients received care, who provided it, plus care type(formal/informal), frequency, and duration. Participants comprised: (i)patients attending rheumatology outpatients at Salford Royal Hospital and (ii)participants with inflammatory polyarthritis enrolled in the Norfolk Arthritis Register (NOAR). Descriptive statistics compared care received, while a logistic regression model investigated factors associated with receiving help.</p><p><strong>Results: </strong>The Salford cohort were younger and had a wider range of RMDs compared to NOAR. A significant number of participants in the Salford(85%) and NOAR(38%) groups required help with daily activities. Of those needing help, 61% and 73% received care in Salford and NOAR respectively, predominantly informally from family and friends. Local authorities delivered social care to just 0.5% Salford and 1.4% NOAR participants. Daily care was provided to 43% of Salford and 53% of NOAR participants. Weekly care duration varied; 21% of Salford and 31% of NOAR responders receiving ≤4 hours, while 19% of Salford and 10% of NOAR responders receiving >20 hours. Having multiple conditions increased the likelihood of receiving care, OR(95%CI): Salford 1.93(1.18-3.18) and NOAR: 3.30(1.45-7.60).</p><p><strong>Conclusion: </strong>The survey highlights a lack of formal care for patients with RMDs, who mostly rely on undocumented informal care. Patients with multiple conditions often require daily living assistance; rheumatology services should consider incorporating social care reviews as part of routine practice.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147363665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Facilitating Expedited Drug Approval-the Past, Present, and Future of Clinical Trials for Pediatric Rheumatic Disease.","authors":"Pamela F Weiss, Hermine I Brunner","doi":"10.1002/acr.80028","DOIUrl":"10.1002/acr.80028","url":null,"abstract":"","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147281992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minimal Important Change and Minimal Clinically Important Difference in Pain and Function With Exercise in Hip Osteoarthritis.","authors":"Yareni Guerrero, Fiona Dobson, Venkatesha Venkatesha, Kim Allison, Gabrielle Knox, Libby Spiers, Travis Haber, David J Hunter, Michelle Hall","doi":"10.1002/acr.80029","DOIUrl":"10.1002/acr.80029","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to estimate the minimal important change (MIC) and minimal clinically important difference (MCID) for pain and physical function in individuals with hip osteoarthritis (OA) following a physiotherapist-guided exercise intervention.</p><p><strong>Methods: </strong>Secondary analysis from a randomized controlled trial of 196 adults with hip OA allocated one of two nine-month exercise programs. Patient-reported outcomes measures for hip pain severity (Numeric Rating Scale [NRS], Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC] pain subscale) and physical function (WOMAC physical function subscale, Patient-Specific Functional Scale [PSFS]) were collected at baseline and three and nine months. Global ratings of change in pain and physical function at three and nine months served as anchors.</p><p><strong>Results: </strong>MIC estimates were 2.1 and 2.4 points for NRS pain at three and nine months, respectively; 2.8 and 3.0 points for WOMAC pain at three and nine months, respectively; 8.7 and 8.3 points for WOMAC physical function at three and nine months, respectively; and -2.1 and -2.0 points for PSFS at three and nine months, respectively. The MCID estimates were 2.0 and 2.4 points for NRS pain at three and nine months, respectively; 2.8 and 3.0 points for WOMAC pain at three and nine months, respectively; 9.2 and 8.3 points for WOMAC physical function at three and nine months, respectively; and -3.5 and -0.7 points for PSFS at three and nine months, respectively.</p><p><strong>Conclusion: </strong>This study provides robust, context-specific MIC and MCID estimates for outcomes in hip OA following exercise. These values can inform the interpretation and design of exercise-based clinical trials for hip OA.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147281956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Systemic Lupus Erythematosus in Australia, 2010-2022: A Population-Based Study Using Linked National Administrative Health Data.","authors":"Lucinda Roper, Rachel Black, Joanna Tieu, Winnie Chen, Matthew Parker, Catherine Hill, Natasha Nassar, Mandana Nikpour","doi":"10.1002/acr.80026","DOIUrl":"10.1002/acr.80026","url":null,"abstract":"<p><strong>Objective: </strong>Systemic lupus erythematosus (SLE) is a heterogenous inflammatory condition with widely varying global prevalence estimates. The frequency of SLE in the general population of Australia has been reported to be notably lower than contemporary estimates in countries such as the United States or United Kingdom, at 19 to 39 per 100,000 as opposed to 65 to 97 per 100,000. This study aimed to develop a national SLE cohort using linked administrative data sets and to estimate prevalence using this approach.</p><p><strong>Methods: </strong>We developed an algorithm to identify SLE cases using the National Health Data Hub, a linked national administrative data asset, which includes data on medications dispensed and medical services subsidized under Australia's universal subsidized coverage schemes, hospital admissions, and deaths. These classification criteria were developed with an expert panel of rheumatologists. Individuals were classified as \"certain,\" \"uncertain,\" or \"no SLE.\" Cohort characteristics were described, and period prevalence (2010-2022) was calculated.</p><p><strong>Results: </strong>A cohort of 26,788 individuals with SLE were identified, which comprised 16,294 certain cases and 10,494 uncertain cases. The period prevalence of SLE in Australia from 2010 to 2022 was 77 to 127 per 100,000 (certain cases or overall cases). Among the certain cases, just over half had received care for SLE only in an outpatient setting.</p><p><strong>Conclusion: </strong>This is the first Australian SLE study using comprehensive linked administrative health data, and it identified higher prevalence than previously reported, more closely aligning with international estimates. This algorithm may serve as a foundation for future Australian and international studies seeking to identify SLE in administrative health data sets.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147281940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}